Druggability & Clinical Context
Druggability
Medium
Score: 0.46
Druggability Analysis
Structural Tractability0.85
Key Metrics
PDB Structures:
39
Known Drugs:
3
Approved:
0
In Clinical Trials:
2
Drug Pipeline (3 compounds)
2 Phase II
Druggability Rationale: CASP1 (Caspase-1) represents a high-druggability target for neurodegeneration, with validated small molecule inhibitors like VX-765 demonstrating promising preclinical and clinical potential. The availability of multiple high-resolution structural models (39 PDB entries, best resolution 1.45Å) and existing phase 2 inhibitors suggest robust tractability for developing targeted neuroinflammatory interventions. The successful progression of covalent small molecule inhibitors through clinical trials indicates a promising drug discovery trajectory for modulating inflammatory neurodegeneration processes.
Mechanism: Small molecule covalent inhibitor of caspase-1 proteolytic activity
Drug Pipeline (3 compounds)
2 Phase II
Known Drugs:VX-765 (clinical_trial) — Epilepsy
CHEMBL2105721 (phase_2)
CHEMBL2107819 (phase_2)
Structural Data:PDB (39) ✓AlphaFold ✓Cryo-EM ✓
Selectivity & Safety Considerations
Selectivity within the caspase family (particularly against CASP4, CASP5, and CASP11) is a key challenge due to homologous active sites; however, covalent inhibition of the catalytic cysteine can provide improved isoform discrimination. Off-target effects on other cysteine proteases must be carefully evaluated during lead optimization.